Research Article

You have full text access to this OnlineOpen article

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

  1. Ferdinand C. Breedveld1,†,*,
  2. Michael H. Weisman2,†,
  3. Arthur F. Kavanaugh3,†,
  4. Stanley B. Cohen4,†,
  5. Karel Pavelka5,
  6. Ronald van Vollenhoven6,†,
  7. John Sharp7,†,
  8. John L. Perez8,†,
  9. George T. Spencer-Green8,†

Article first published online: 29 DEC 2005

DOI: 10.1002/art.21519

Issue

Arthritis & Rheumatism

Arthritis & Rheumatism

Volume 54, Issue 1, pages 26–37, January 2006

Additional Information

How to Cite

Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F., Cohen, S. B., Pavelka, K., Vollenhoven, R. v., Sharp, J., Perez, J. L. and Spencer-Green, G. T. (2006), The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis & Rheumatism, 54: 26–37. doi: 10.1002/art.21519

Author Information

  1. 1

    Leiden University Medical Center, Leiden, The Netherlands

  2. 2

    Cedars-Sinai Medical Center, Los Angeles, California

  3. 3

    University of California San Diego Center for Innovative Therapy, La Jolla

  4. 4

    University of Texas Southwestern Medical Center, Dallas

  5. 5

    Institute of Rheumatology, Prague, Czech Republic

  6. 6

    Karolinska Hospital, Stockholm, Sweden

  7. 7

    University of Washington, Seattle

  8. 8

    Abbott Laboratories, Parsippany, New Jersey

  1. †

    Dr. Breedveld has received consulting fees or honoraria (less than $10,000 per year) from Centocor, Schering-Plough, Amgen/Wyeth, and Abbott. Dr. Weisman has received consulting fees or honoraria (less than $10,000 per year) from Abbott, Bristol-Myers Squibb, Centocor, Amgen/Wyeth, Roche, Human Genome Sciences, Elan/Biogen, Regeneron, and Genentech. Dr. Kavanaugh has performed clinical studies for Abbott, Amgen, Centocor, Biogen-Idec, Bristol-Myers Squibb, and Genentech. Dr. Cohen has received consulting fees or honoraria (less than $10,000 per year) from Abbott, Genentech, Biogen IDEC, Scios, Amgen, Sanofi-Aventis, Chelsea Therapeutics, and Xencor. Dr. van Vollenhoven has received consulting fees or honoraria (less than $10,000 per year) from Abbott, Centocor, Schering-Plough, and Wyeth. Dr. Sharp has received consulting fees or honoraria (more than $10,000 per year) from Abbott, Amgen, Aventis, Centocor, Fujisawa, and Wyeth and consulting fees or honoraria (less than $10,000 per year) from Bristol-Myers Squibb and Schering. Dr. Perez is a member of Abbott's stock retirement plan. Dr. Spencer-Green owns stock in Abbott.

*Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4-R Postbox 9600, Leiden 2300 RC, The Netherlands

Publication History

  1. Issue published online: 29 DEC 2005
  2. Article first published online: 29 DEC 2005
  3. Manuscript Accepted: 21 SEP 2005
  4. Manuscript Received: 31 MAR 2005

Funded by

  • Abbott Laboratories

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (279K)

REFERENCES

  • 1
    Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903–11.
  • 2
    Van der Heidje D, van Leeuwen MA, van Riel PL, van de Putte L. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol 1995; 22: 1792–6.
  • 3
    Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003; 62: 611–6.
  • 4
    Hulsmans HM, Jacobs JW, van der Heidje DM, van Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000; 43: 1927–40.
    Direct Link:
  • 5
    Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002; 61: 1055–9.
  • 6
    Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002; 41: 1346–56.
  • 7
    Sokka T, Hannonen P. Utility of disease modifying antirheumatic drugs in sawtooth strategy: a prospective study of early rheumatoid arthritis patients up to 15 years. Ann Rheum Dis 1999; 58: 618–22.
  • 8
    Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998; 41: 1571–82.
    Direct Link:
  • 9
    Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004; 50: 2082–93.
    Direct Link:
  • 10
    Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999; 26: 1681–5.
  • 11
    Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009–17.
    Direct Link:
  • 12
    Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996; 35: 1101–5.
  • 13
    Sharp J, van der Heidje D, Boers M, Boonen A, Bruynesteyn K, Emery P, et al. Repair of erosions in rheumatoid arthritis does occur: results from 2 studies by the OMERACT Subcommittee on Healing of Erosions. J Rheumatol 2003; 30: 1102–7.
  • 14
    Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137–45.
    Direct Link:
  • 15
    Baumgartner SW, Fleischmann R, Moreland L, Schiff M, Markenson J, Whitmore J. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol 2004; 31: 1532–7.
  • 16
    Hawley DJ, Wolfe F. Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short-term clinical trials and observational studies versus long-term observational studies. Arthritis Care Res 1992; 5: 130–6.
    Direct Link:
  • 17
    Wolfe F, Pincus T. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. J Rheumatol 2001; 28: 1817–1824.
  • 18
    Pincus T, Sokka T. Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care. Rheumatology (Oxford) 2004; 30: 725–51.
  • 19
    Pincus T, Strand V, Koch G, Amara I, Crawford B, Wolfe F, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 2003; 48: 625–30.
    Direct Link:
  • 20
    Pincus T, Sokka T. Partial control of core data set measures and Disease Activity Score (DAS) measures of inflammation does not prevent long-term joint damage: evidence from longitudinal observations over 5–20 years. Clin Exp Rheumatol 2002; 20(5 Suppl 27 ): S42–7.
  • 21
    Krishnan E, Fries J. Reduction in long-term functional disability in rheumatoid arthritis from 1977 to 1998: a longitudinal study of 3035 patients. Am J Med 2003; 115: 371–6.
  • 22
    Van der Heidje D. Impact of rheumatoid arthritis on physical function during the first five years: no longer a question mark? Rheumatology (Oxford) 2000; 39: 579–580.
  • 23
    Sokka T, Pincus T. Markers for work disability in rheumatoid arthritis. J Rheumatol 2001; 28: 1718–22.
  • 24
    Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347–56.
    Direct Link:
  • 25
    Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. Delay to institution of therapy and induction of remission using single-drug or combination–disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894–8.
    Direct Link:
  • 26
    Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M'Seffar A, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000; 27: 623–9.
  • 27
    O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? [editorial]. Arthritis Rheum 2002; 46: 283–5.
    Direct Link:
  • 28
    O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1164–70.
    Direct Link:
  • 29
    O'Dell J, Haire E, Erikson N, Drymalski W, Palmer W, Eckhoff P, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 1287–91.
  • 30
    Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med 1999; 131: 768–74.
  • 31
    Klareskog L, van der Heidje D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675–81.
  • 32
    St.Clair EW, van der Heidje DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432–43.
    Direct Link:
  • 33
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 34
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35.
    Direct Link:
  • 35
    Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998; 41: 1564–70.
  • 36
    Van der Heijde DM. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999; 26: 743–5.
  • 37
    Pincus T, Sokka T, Kavanaugh A. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for near remission of DAS or single measures. Clin Exp Rheumatol 2004; 22(5 Suppl 35 ): S50–6.
  • 38
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh Ls, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400–11.
    Direct Link:
  • 39
    Prevoo MLL, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8.
    Direct Link:
  • 40
    Fransen J, Creemers MCW, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 1252–5.
  • 41
    Food and Drug Administration. Guidance for industry clinical development programs for drugs, devices, and biological products for thetreatment of rheumatoid arthritis (RA). URL: http://www.fda.gov/cder/guidance/1208fnl.pdf.
  • 42
    Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002; 46: 2294–300.
    Direct Link:
  • 43
    Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005; 32: 1232–42.
  • 44
    Bathon JM, Martin RW, Fleischmann R, Tesser JR, Schiff M, Keystone E, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93.
  • 45
    Strand V, Landewe R, van der Heidje D. Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis [abstract]. Ann Rheum Dis 2002; 61(Suppl 2): ii64.
  • 46
    Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003; 30: 1138–46.
  • 47
    Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 1238–44.
  • 48
    Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: by what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? [review]. Arthritis Rheum 2001; 44: 1977–83.
    Direct Link:
  • 49
    Spencer-Green G, Warren MS, Whitmore J, Djian J, Pedersen R. Effects of etanercept (ENBREL) in patients with chronic heart failure: results of RENAISSANCE and RECOVER trials [abstract]. Arthritis Rheum 2002; 46 Suppl 9: S520.
  • 50
    Mohan A, Cote T, Siegel J, Braun M. Infectious complications of biologic treatments of rheumatoid arthritis. Curr Opin Rheumatol 2003; 15: 179–84.
  • 51
    Ellerin T, Rubin RH, Weinblatt ME. Infections and anti–tumor necrosis factor α therapy [review]. Arthritis Rheum 2003; 48: 3013–22.
    Direct Link:
  • 52
    Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372–9.
    Direct Link:
  • 53
    Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-α antagonists. Drug Safety 2004; 27: 307–24.
  • 54
    Imperato AK. Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 2004; 16: 199–205.
  • 55
    Khanna D, McMahon M, Furst DE. Anti–tumor necrosis factor α therapy and heart failure: what have we learned and where do we go from here? [review]. Arthritis Rheum 2004; 50: 1040–50.
    Direct Link:
  • 56
    Mohan A, Cote T, Block J, Manadan A, Siegel J, Braun M. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39: 295–9.
  • 57
    Ormerod LP. Tuberculosis and anti-TNF-α treatment [editorial]. Thorax 2004; 59: 921.
  • 58
    Wolfe F, Michaed K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50: 1740–51.
    Direct Link:
  • 59
    Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151–8.
    Direct Link:
  • 60
    Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker D, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993; 85: 307–11.
  • 61
    Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-α—California, 2002–2003. MMWR Morb Mortal Wkly Rep 2004; 53: 683–6.
  • 62
    Hamilton CD. Tuberculosis in the cytokine era: what rheumatologists need to know [editorial]. Arthritis Rheum 2003; 48: 2085–91.
    Direct Link:
  • 63
    Keane J, Gershon S, Wise RP, Mirabile L, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001; 345: 1098–104.
  • 64
    Winthrop K, Siegel J. Tuberculosis cases associated with infliximab and etanercept. Clin Infect Dis 2004; 39: 1256–7.
View Full Article (HTML) Get PDF (279K)